Literature DB >> 8852475

Treatment failure in erythema migrans--a review.

K Weber1.   

Abstract

Patients with erythema migrans can fail to respond to antibiotic therapy. Persistent or recurrent erythema migrans, major sequelae such as meningitis and arthritis, survival of Borrelia burgdorferi and significant and persistent increase of antibody titres against B. burgdorferi after antibiotic therapy are strong indications of a treatment failure. Most, if not all, antibiotics used so far have been associated with a treatment failure in patients with erythema migrans. Roxithromycin and erythromycin are definitely or probably ineffective. However, doxycycline, amoxicillin, cefuroxime, ceftriaxone, azithromycin and high-dose penicillin V perform comparably well.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852475     DOI: 10.1007/bf01780663

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  15 in total

1.  Successful treatment of erythema migrans Afzelius.

Authors:  E HOLLSTROM
Journal:  Acta Derm Venereol       Date:  1951       Impact factor: 4.437

2.  Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans.

Authors:  K Weber; V Preac-Mursic; U Neubert; R Thurmayr; P Herzer; B Wilske; G Schierz; W Marget
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 3.  Clinical management of Lyme borreliosis.

Authors:  K Weber; H W Pfister
Journal:  Lancet       Date:  1994-04-23       Impact factor: 79.321

4.  Treatment of the early manifestations of Lyme disease.

Authors:  A C Steere; G J Hutchinson; D W Rahn; L H Sigal; J E Craft; E T DeSanna; S E Malawista
Journal:  Ann Intern Med       Date:  1983-07       Impact factor: 25.391

5.  Serological diagnosis of erythema migrans disease and related disorders.

Authors:  B Wilske; G Schierz; V Preac-Mursic; K Weber; H W Pfister; K Einhäupl
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

6.  [Erythema chronicum migrans meningitis - a bacterial infectious disease? (author's transl))].

Authors:  K Weber
Journal:  MMW Munch Med Wochenschr       Date:  1974-11-08

7.  Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

Authors:  K Hansen; A Hovmark; A M Lebech; K Lebech; I Olsson; L Halkier-Sørensen; E Olsson; E Asbrink
Journal:  Acta Derm Venereol       Date:  1992-08       Impact factor: 4.437

8.  Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin.

Authors:  F Strle; E Ruzic; J Cimperman
Journal:  J Antimicrob Chemother       Date:  1992-10       Impact factor: 5.790

9.  Polymerase chain reaction for detection of Borrelia burgdorferi DNA in skin lesions of early and late Lyme borreliosis.

Authors:  L V von Stedingk; I Olsson; H S Hanson; E Asbrink; A Hovmark
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

10.  Azithromycin versus penicillin V for the treatment of early Lyme borreliosis.

Authors:  K Weber; B Wilske; V Preac-Mursic; R Thurmayr
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

View more
  5 in total

1.  PCR-Based quantification of Borrelia burgdorferi organisms in canine tissues over a 500-Day postinfection period.

Authors:  R K Straubinger
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Lyme borreliosis--an overdiagnosed disease?

Authors:  B Svenungsson; G Lindh
Journal:  Infection       Date:  1997 May-Jun       Impact factor: 3.553

3.  Erythromycin resistance in Borrelia burgdorferi.

Authors:  Darya Terekhova; Marina L Sartakova; Gary P Wormser; Ira Schwartz; Felipe C Cabello
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 4.  Borreliella burgdorferi Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes.

Authors:  Felipe C Cabello; Monica E Embers; Stuart A Newman; Henry P Godfrey
Journal:  mBio       Date:  2022-04-25       Impact factor: 7.786

5.  Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.

Authors:  Heidelore Hofmann; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Andreas Krause; Sebastian Rauer; Bernhard Ruf
Journal:  Ger Med Sci       Date:  2017-09-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.